Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems
PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas® SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas® 6800/8800 Systems. This non-invasive test is for any individual, including those suspected of COVID-19 and those without symptoms. Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
- PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.
- Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
- "Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people.
- The test also provides patients with the option to self-collect their saliva sample on site, following the instructions of a healthcare professional.